Identification of cytotoxic drugs that selectively target tumor cells with MYC overexpression

Anna Frenzel1, Hanna Zirath, Marina Vita

  • 1Department of Microbiology Tumor and Cell Biology (MTC), Karolinska Institutet, Stockholm, Sweden.

Plos One
|December 2, 2011
PubMed

Insights

MYC overexpression in cancer cells sensitizes them to specific cytotoxic drugs, including those targeting microtubules and topoisomerases. This finding highlights MYC as a potential therapeutic target for various cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • MYC oncoprotein deregulation is common in many human cancers, correlating with aggressive disease and poor differentiation.
  • Targeting MYC-overexpressing cancer cells with specific compounds offers a potential therapeutic strategy.

Purpose of the Study:

  • To identify conventional cytotoxic compounds that selectively reduce viability and/or growth in cells overexpressing MYC (MYCN or c-MYC).
  • To investigate the mechanisms by which MYC overexpression influences cellular responses to cytotoxic agents.

Main Methods:

  • Screening of 80 conventional cytotoxic compounds using cell lines with conditional MYCN or c-MYC expression.
  • Assessing compound-induced apoptosis and proliferation inhibition in a MYC-dependent manner.
  • Analyzing compound mechanisms of action, including effects on microtubules, topoisomerases, and nucleic acid/protein synthesis.

Main Results:

  • Approximately 25% of screened compounds demonstrated MYC-specific activity, with effects often enhanced by MYC or MYCN overexpression.
  • Active compounds targeted diverse cellular pathways, including microtubule dynamics, topoisomerase activity, and DNA/RNA/protein synthesis.
  • Topoisomerase I inhibitors reduced MYC protein levels, while doxorubicin and MYRA-A disrupted MYC-Max interaction.

Conclusions:

  • MYC overexpression sensitizes cancer cells to specific cytotoxic drug classes, indicating MYC pathway involvement in drug response.
  • A subset of conventional cytotoxic drugs targets the MYC pathway, suggesting potential for optimizing cancer therapy.
  • Cellular screening of chemical libraries is effective for identifying compounds with MYC-specific biological activity, supporting MYC as a therapeutic target.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...